Walmart, CVS, Costco and Amazon are using direct-to-consumer weight-loss drug programs to build long-term pharmacy relationships as more employers drop benefits for Wegovy and Zepbound.
Large retailers and pharmacy chains are moving to capture more GLP-1 prescription demand as employers scale back coverage for weight-loss drugs, pushing more patients toward direct-to-consumer programs. Walmart, CVS, Costco and Amazon are treating those programs as a way to win recurring pharmacy business and broader household spending, with analysts describing obesity care as a long-term customer relationship rather than a one-time prescription sale. The shift is being driven in part by cost pressure on employers. A Mercer survey last month found 6% of large employers dropped GLP-1 coverage this year, while the drugs' share of claims rose to 11.4% from 6.9% in 2023. Cigna said earlier this month it would stop covering the medicines for its own employees. As coverage fades, retailers are stepping in with cash-pay and membership-based offers, including LillyDirect pricing of $299 to $449 a month, NovoCare introductory pricing of $199 that later rises to $349, Costco's Sesame partnership at around $349 for Wegovy with membership required, and Amazon One Medical offers for insured patients starting as low as $25 a month. Retail chains see refill behavior as especially valuable because it creates repeated contact with customers and can anchor spending across prescriptions, groceries and general merchandise. Walmart, which has nearly 4,600 pharmacies and 4.8% of the pharmacy market according to Drug Channels Institute, expanded its Better Care Services platform in April to combine GLP-1 prescriptions with nutrition coaching, fitness apps and AI-driven coaching tools. Amazon also launched a GLP-1 management program in April through Amazon One Medical and Amazon Pharmacy, with same-day delivery in nearly 3,000 cities and plans to reach 4,500 by year-end. The strategy also reflects a broader retailer push into weight-management platforms, virtual obesity care, nutrition coaching, metabolic health solutions and employer care management. But the economics may favor large chains over smaller operators. Seth Friedman of Gallagher said independent pharmacies stand to lose volume, while Kansas pharmacy owner Dared Price said customers are already shifting to CVS and Costco, leaving smaller pharmacies with less visibility into patients' full medication use and potentially missing dangerous drug interactions involving medicines such as insulin or oral contraceptives. CVS said its pharmacists are equipped to support patients beyond simply dispensing medication. The company said participation in NovoCare is one option, and that it also takes part in Medicare Bridge, a Centers for Medicare & Medicaid Services (U.S. health agency) initiative launched July 1 that offers eligible Medicare patients GLP-1s for weight loss at a flat $50 monthly copay through a central processor. Some obesity-care specialists say the focus on the lowest price risks fragmenting care and overlooking the broader clinical support patients need.